SCHEDULE: ARK Investment Management Discloses Arcturus Therapeutics Stake

ARK Investment Management LLC and Catherine D. Wood have jointly filed a Schedule 13G, reporting beneficial ownership of 10.37% of Arcturus Therapeutics Holdings Inc. common stock as of April 30, 2026.

Summary

• ARK Investment Management LLC and Catherine D. Wood have filed an amendment to their Schedule 13G, reporting their beneficial ownership of Arcturus Therapeutics Holdings Inc. common stock.
• As of April 30, 2026, the total beneficial ownership reported is 2,947,556 shares, representing 10.37% of the class of securities.
• ARK Investment Management LLC holds sole voting and dispositive power over these shares, while Catherine D. Wood shares voting and dispositive power.
• The filing indicates that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, indicating strong conviction from a prominent growth-focused investor in Arcturus Therapeutics' technology and potential.

Positives

• ARK Investment Management's increased stake suggests confidence in Arcturus Therapeutics' long-term prospects.
• The reporting of a significant ownership percentage (10.37%) can signal a strong conviction by a notable institutional investor.

Risks

• The filing does not contain specific forward-looking statements or risk factors related to Arcturus Therapeutics' business operations, as it is a disclosure of ownership.
• Potential risks for Arcturus Therapeutics would be detailed in their other SEC filings, not this Schedule 13G.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Arcturus Therapeutics' future performance.

Industry Context

StockSavvy.ai notes that ARK Investment Management is known for its focus on disruptive innovation, particularly in areas like genomics and biotechnology. Their increased stake in Arcturus Therapeutics, a company focused on RNA-based medicines, aligns with ARK's investment thesis in cutting-edge healthcare technologies.

Stakeholder Impact

• Shareholders may view ARK's increased stake as a positive signal of institutional confidence, potentially influencing market perception.
• Employees and management of Arcturus Therapeutics may see this as validation of their strategy and technology.
• Creditors and suppliers may interpret the increased institutional ownership as a sign of greater financial stability and long-term viability.

Next Steps

• Continued monitoring of ARK Investment Management's stake and any future filings related to Arcturus Therapeutics.
• Review of Arcturus Therapeutics' own SEC filings for operational and financial updates.

Key Dates

Recommendation

This filing primarily discloses ownership changes by a significant institutional investor. While ARK's increased stake suggests confidence, it does not provide new operational or financial data for Arcturus Therapeutics. Therefore, a 'hold' recommendation is appropriate, pending further company-specific performance updates.

Keywords

Arcturus Therapeutics, ARK Investment Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology